Physician profile
Nathan Pecha
NPI 1073182010
$3,320.89
in general payments reported to CMS, 2019-2025
18 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $407 · 2022: $577 · 2023: $681 · 2024: $507 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,249 · Entertainment: $88.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,249.33 |
| Entertainment | $88.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $693.59 | 2022-2025 | Tryptyr, Unity, Clareon Panoptix Pro |
| Rxsight INC | $585.75 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Glaukos Corporation | $318.45 | 2021-2024 | Photrexa |
| Eyevance Pharmaceuticals LLC | $247.33 | 2021-2022 | |
| Astellas Pharma US INC | $241.77 | 2023-2024 | Izervay |
| Ocular Therapeutix, INC. | $181.48 | 2024-2025 | Dextenza |
| Sun Pharmaceutical Industries INC. | $163.44 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $155.69 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $118.43 | 2022-2025 | Acuvue |
| Rayner Intraocular Lenses Limited | $109.54 | 2024-2025 | Rayone Aspheric, Rayner Cataract Set 1, Rayone Emv |
| Dompe US, INC. | $109.47 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $95.47 | 2023-2025 | Tyrvaya, Ryzumvi |
| Optos, INC. | $88.18 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Abbvie INC. | $81.37 | 2024-2025 | |
| Carl Zeiss Meditec USA, INC. | $70.95 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $23.60 | 2023 | |
| Amgen INC. | $19.02 | 2025 | Tepezza |
| Thea Pharma INC. | $17.36 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Pecha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.